Chemically prepared fats and Crohn disease: a pilot study of the occurrence of trans-fatty acids in the subcutaneous tissue of Crohn patients in comparison with healthy controls as a parameter of long-term fat intake
Track these metrics weekly: Dose administered (mg, units, date, and time) Injection site (for rotation tracking) Side effects (type, severity 1 to 10, duration) Body weight (same time, same conditions each week) Body measurements (waist, hips, chest, if relevant) Appetite changes (subjective 1 to 10 scale) Energy levels (subjective 1 to 10 scale) Vial tracking (reconstitution date, volume remaining, expiration) This data tells you whether your dose is right, when to escalate, and whether the protocol is producing the desired outcomes
But when you add it in with the Mcverteuron, we end up with one plus one equaling four
After propensity score matching (16,076 pairs) and 2.2 years mean follow-up duration, use of GLP1-RA in patients with moderate to advanced CKD was associated with lower annual rate of acute healthcare utilization and all-cause mortality
